Deltadot has appointed Richard Lingard as VP sales with immediate effect, to drive the commercial growth of the company's Peregrine protein analysis solution
Prior to joining Deltadot, Richard Lingard was a director of strategic alliances at Invitrogen.
Previously, he was VP of business development at Argenta Discovery, director of business development at Inpharmatica, now part of Galapagos, and director of sales based at the US headquarters of Geneomica, now part of Exelixis.
Lingard also held business positions at Accerys, and Merck.
A business trained chemist, Lingard has a BSc from Umist, now Manchester University.
Commenting on the new appointment, Tony Baxter, CEO of Deltadot said: "I am delighted to announce this appointment.
"Richard will play a key role in driving the commercial growth of Deltadot's Peregrine protein and DNA analysis solution and in the roll-out of the company's product pipeline as we introduce our other advanced technologies and products.
"Having worked very successfully with Richard at Argenta Discovery, I am confident he has the experience, vision and drive to ensure Deltadot's commercial success".
Lingard commented: "Deltadot's products are focused on improving the effectiveness and efficiency in all segments of drug discovery and disease diagnosis.
"I am pleased to join the team at this exciting time and to be working with a company that is set to be the market leader for label-free analysis of biomolecules."
